Prediction of COVID-19 mortality using machine learning strategies and a large-scale panel of plasma inflammatory proteins: A cohort study

Medicina Intensiva (English Edition), Journal Year: 2025, Volume and Issue: unknown, P. 502200 - 502200

Published: April 1, 2025

Language: Английский

---

BA.1 breakthrough infection elicits distinct antibody and memory B cell responses in vaccinated-only versus hybrid immunity individuals

iScience, Journal Year: 2025, Volume and Issue: 28(4), P. 111962 - 111962

Published: Feb. 6, 2025

Immune memory is influenced by the frequency and type of antigenic challenges. Here, we performed a cross-sectional comparison immune parameters following BA.1 breakthrough infection in individuals with prior hybrid immunity (conferred vaccination) versus those solely vaccinated cohort health care workers Lyon, France. The results showed higher levels serum anti-receptor binding domain (RBD) antibodies neutralizing against post-infection vaccine-only group. Individuals this group also decrease B cells ancestral strain but an increase specific cross-reactive to BA.1, suggesting more limited imprinting. Conversely, prevents antibody dependent cellular cytotoxicity (ADCC) response, possibly limiting IgG4 class-switching enhanced anti-N responses post-infection. This highlights that induces different depending on history vaccination infection, which should be considered for further guidelines.

Language: Английский

---

Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 293 - 293

Published: March 10, 2025

Background. The pathogenic coronaviruses (CoVs) MERS-CoV and SARS-CoV-2, which are responsible for the MERS outbreak COVID-19 pandemic, respectively, continue to infect humans, with significant adverse outcomes. There is a continuing need develop mucosal vaccines against these respiratory viral pathogens prevent entry replication at sites. receptor-binding domain (RBD) of CoV spike (S) protein critical vaccine target, glycan masking unique approach designing subunit improved neutralizing activity. Methods. We evaluated efficacy immunity, broad activity, cross-protection afforded by combined glycosylated encoding RBDs original SARS-CoV-2 strain (SARS2-WT-RBD), Omicron-XBB.1.5 variant (SARS2-Omi-RBD), (MERS-RBD). Results. Intranasal administration three-RBD cocktail induced effective, durable IgA systemic IgG antibodies specific S CoVs, thereby infection pseudotyped SARS-CoV-2-WT, Omicron-XBB.1.5, MERS-CoV. protected immunized mice from challenge MERS-CoV, leading reduction in titers lungs. By contrast, individual RBD proteins only such immune responses either or protecting subsequent MERS-CoV; they did not provide simultaneous protection both CoVs. Conclusions. This study describes strategy efficacious that induce cross-neutralizing highlighting potential design other pathogens.

Language: Английский

---

Microneedle Delivery of Heterologous Microparticulate COVID-19 Vaccine Induces Cross Strain Specific Antibody Levels in Mice

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 380 - 380

Published: April 1, 2025

Background: In recent years, the COVID-19 pandemic has significantly impacted global health, largely driven by emergence of various genetic mutations within SARS-CoV-2 virus. Although phase passed, full extent virus’s evolutionary trajectory remains uncertain, highlighting need for continued research in vaccine development to establish a cross-reactive approach that can effectively address different variants. This proof-of-concept study aimed assess effectiveness microparticulate delivery through minimally invasive microneedle route administration, using heterologous prime–booster strategy against Method: uses whole inactivated virus Delta variant prime dose and Omicron booster dose, with alum as an adjuvant. The formulation microparticles involves encapsulating antigens poly lactic-co-glycolic acid (PLGA) polymer, which provides sustained release enhances immunogenicity while protecting antigen. Microparticles were tested vitro assays, characterization included particle size, zeta potential, encapsulation efficacy. Furthermore, serum was collected post-administration mice antibody levels. Result: assays confirmed non-cytotoxicity ability activate immune response particles. Administering this via microneedles proven effective delivering vaccines skin. We also observed higher antigen-specific levels cross-reactivity strains. Conclusions: Our adjuvanted microparticulate-based showed among strains successfully delivered microneedles.

Language: Английский

---

Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats

Vaccine, Journal Year: 2025, Volume and Issue: 56, P. 127183 - 127183

Published: May 1, 2025

Language: Английский

---